Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INS50589 Infusion · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INS50589 Intravenous Infusion | DRUG | - |
Inclusion Criteria: * Have body mass index (BMI) between 18.5 kg/m2 and 35 kg/m2 and body weight no greater than 120 kg. * If female, must not be pregnant or lactating, and if of childbearing potential or sexually active, must use acceptable method of birth control. Exclusion Criteria: * Have cli...
INS50589 Infusion is an investigational small molecule being developed for cardiovascular disease. It is administered as an intravenous infusion. The drug is currently in Phase 1 clinical development, meaning it is still being tested in clinical trials and is not yet approved for any use.
INS50589 Infusion is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this investigational drug for cardiovascular disease.
INS50589 Infusion is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied for cardiovascular disease, and its Phase 1 trial has been completed.
INS50589 Infusion has one completed clinical trial, identified as NCT00099450. This Phase 1 study evaluated the tolerability, pharmacokinetics, and pharmacodynamics of the drug in healthy volunteers. The trial enrolled 48 participants in the United States.
INS50589 Infusion is the intravenous formulation of the investigational drug INS50589. The name "INS50589 Infusion" specifically refers to the drug when administered as an intravenous infusion, as studied in clinical trials for cardiovascular disease.